Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping.
about
Translating cancer genomes and transcriptomes for precision oncologyNext-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and ChallengesMolecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularAdvances in the Molecular Analysis of Soft Tissue Tumors and Clinical ImplicationsDetection of Genomic Structural Variants from Next-Generation Sequencing DataGenetic profiling to determine risk of relapse-free survival in high-risk localized prostate cancer.Multi-factor data normalization enables the detection of copy number aberrations in amplicon sequencing data.Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data.Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing.Targeted next-generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas.Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for MolecularApplication of ion torrent sequencing to the assessment of the effect of alkali ballast water treatment on microbial community diversity.Highly sensitive amplicon-based transcript quantification by semiconductor sequencingHigh-throughput sequencing and copy number variation detection using formalin fixed embedded tissue in metastatic gastric cancer.Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.Comparison of custom capture for targeted next-generation DNA sequencingSingle-tube, highly parallel mutation enrichment in cancer gene panels by use of temperature-tolerant COLD-PCR.Advancing clinical oncology through genome biology and technology.Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortiumRetrospective review using targeted deep sequencing reveals mutational differences between gastroesophageal junction and gastric carcinomas.Clinical validation of KRAS, BRAF, and EGFR mutation detection using next-generation sequencing.Circulating tumor cells in hepatocellular carcinoma: a pilot study of detection, enumeration, and next-generation sequencing in cases and controls.Development and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Identification of variants in primary and recurrent glioblastoma using a cancer-specific gene panel and whole exome sequencingEvaluation of two highly-multiplexed custom panels for massively parallel semiconductor sequencing on paraffin DNAOncogenic mutations in melanomas and benign melanocytic nevi of the female genital tract.Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.A benchmark study on error-correction by read-pairing and tag-clustering in amplicon-based deep sequencingBuilding a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene TestingIntegration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies.Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations, validated by the QIAGEN Therascreen PCR kit and alternative NGS platform.The NEXT-1 (Next generation pErsonalized tX with mulTi-omics and preclinical model) trial: prospective molecular screening trial of metastatic solid cancer patients, a feasibility analysisIGF1R as a Key Target in High Risk, Metastatic Medulloblastoma.Exploring Genetic Diversity in Plants Using High-Throughput Sequencing Techniques.Association of FGD1 polymorphisms with early-onset breast cancer.Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer.Evaluation of ultra-deep targeted sequencing for personalized breast cancer care.MAX inactivation is an early event in GIST development that regulates p16 and cell proliferation.
P2860
Q26777081-F0E35EFD-A0DC-4E10-82F2-DFBB3EAF2F3AQ26782324-98B754D3-98A1-4008-BF42-134522B43DC1Q26828860-D3CD76DE-2145-48F5-B454-BA52D4DE0655Q27021848-7DEFDF67-A342-48FD-B1C3-DCABDB584854Q28082859-22C1617C-7EE5-4175-A033-3728577B978FQ30573750-FA4FF54F-B24D-493D-8C2C-B4F2406EE22EQ30836209-06355467-2284-45E7-9A06-5B7A164374FCQ30874026-4628F06C-2BBE-4531-ADD3-5DB3748C4077Q31162502-A4FBC119-BD59-4597-98D4-89657E6B24C6Q33740638-39DB3545-064F-4A84-953B-8C7B73DDA845Q33754040-4BB047F4-1343-4C8D-BB50-6333733EB020Q34159011-B23A43E6-1E36-426A-AD87-C54EC24685C5Q34184204-FA0C9494-B2C1-4054-8451-4BCC88D10500Q34428042-A2481D2A-F934-4489-A6A0-7139C762C439Q34456612-1A0AEF30-7B92-41CB-9A93-06360D9A6FC6Q34560270-4314D673-B009-4774-9475-1CF598EBBA41Q34786626-79C3D678-9840-478D-8AAD-0E4C7C390D7EQ34799278-A8900A3D-F5E4-40CE-B735-06ACFD0079DEQ34803010-1055DDA7-0EAE-4985-B8A4-55DDCA5A1DBEQ35053271-83EB9531-26A7-4959-8736-E693F01A707BQ35067345-7740E4F7-D495-4744-BE0E-338C1987A06AQ35095944-B97BF775-3CB0-4164-8CF2-569C6967B7E4Q35440625-371BFB2D-DCE2-43A8-8021-D93337B01C70Q35555483-E630A647-A1A5-4FC6-9163-D2D094C532F0Q35581130-9E25563C-6AB0-4BB3-94B8-0615C25C4674Q35651423-1C52B728-874C-456E-91D0-0E3E18B193D1Q35670595-E456E533-BA45-4ADC-80C2-72FF28257AE4Q35772123-0A3FA0BC-7EDF-4A05-BFB9-6EE5D180E862Q35901968-3A03DC2D-CF19-4763-A31C-38B1CCF36D62Q35921395-6DBF3D1E-6F14-4E9E-8CFD-F40C7123179FQ35979104-41DB3E15-EED7-4A74-B606-80F80A6953C0Q36014165-50F21E23-09A1-4F66-8A9A-4AEC4871BDCDQ36377976-4366B8B7-BFF4-4675-A082-33EFA46EC07BQ36545162-1FEE3BE4-A3C9-4C8B-8C9F-3FD1F03C5BB2Q36965081-F8C553A0-0F7E-4851-9C87-F8354E31B69EQ37112903-BE05C0A8-3D5C-49C0-AD89-48B991685BCFQ37206015-5076E5A4-AE3D-4C0C-8128-15A458A5125CQ37275937-367606C2-8B66-4A10-BECD-B94C74AA6127Q37690220-560BA415-5A9D-41E5-B193-3056DA860C8EQ37692151-E1C0C887-19FE-49D7-8BB6-E9EAD8C1CD4B
P2860
Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping.
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@ast
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@en
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@nl
type
label
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@ast
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@en
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@nl
prefLabel
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@ast
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@en
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@nl
P2093
P1476
Combining highly multiplexed P ...... g for rapid cancer genotyping.
@en
P2093
Carol Beadling
Christopher L Corless
John Leamon
Katherine Rhodes
Mark Andersen
Michael C Heinrich
Michael Thornton
Tanaya L Neff
P304
P356
10.1016/J.JMOLDX.2012.09.003
P577
2012-12-27T00:00:00Z